Form 4: Analog Devices CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Analog Devices CEO Vincent Roche exercised stock options and sold 10,000 shares of common stock pursuant to a pre-arranged 10b5-1 trading plan.
Summary
- Vincent Roche, Chair & CEO of Analog Devices Inc. (ADI), reported transactions on October 1, 2025.
- Roche exercised 10,000 non-qualified stock options at an exercise price of $94.41 per share.
- Concurrently, Roche sold 10,000 shares of Analog Devices common stock at a price of $243.71 per share.
- The sale was executed under a Rule 10b5-1 trading plan, which was adopted by Roche on May 23, 2025.
- Following these transactions, Roche directly owns 140,118.462 shares of common stock.
- Roche also indirectly holds 34,828 shares through the Vincent Roche 2023 Grantor Retained Annuity Trust and 23,515 shares through the Vincent Roche 2024 Grantor Retained Annuity Trust.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan, which is generally considered neutral as it's not based on new, non-public information. It reflects personal financial management rather than a change in company fundamentals or outlook.
Positives
- The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled, non-discretionary sale, which mitigates concerns about insider selling based on new, non-public information.
- The exercise price of $94.41 compared to the sale price of $243.71 indicates a significant personal gain for the CEO from vested options.
Negatives
- The sale of 10,000 shares by the CEO, even if pre-planned, represents a reduction in direct insider ownership.
Risks
- While the sale was pre-planned, some investors may still perceive insider selling as a potential signal, which could lead to minor negative sentiment.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- The indirect beneficial ownership of shares through the Vincent Roche 2023 Grantor Retained Annuity Trust and the Vincent Roche 2024 Grantor Retained Annuity Trust represents related party holdings.
Stakeholder Impact
- Shareholders: The sale of shares by the CEO, even under a 10b5-1 plan, slightly reduces direct insider ownership, which some investors might monitor. However, the pre-planned nature mitigates concerns about adverse implications.
- Employees: No direct impact mentioned.
- Customers/Suppliers/Creditors: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 03/15/2021 | Date when the non-qualified stock option became fully vested. |
| 08/25/2023 | Date of the Vincent Roche 2023 Grantor Retained Annuity Trust. |
| 10/03/2024 | Date of the Vincent Roche 2024 Grantor Retained Annuity Trust. |
| 05/23/2025 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 10/01/2025 | Date of the stock option exercise and subsequent sale of common stock. |
| 10/02/2025 | Date the Form 4 was signed by Shelly Shaw, General Counsel, by Power of Attorney. |
| 03/11/2030 | Expiration date of the non-qualified stock option. |
Keywords
Analog Devices, ADI, Vincent Roche, Form 4, Insider Trading, Stock Option Exercise, 10b5-1 Plan, CEO, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.